BACKGROUND: Probiotic supplementation significantly reduces the risk of necrotising enterocolitis (NEC) and all cause mortality in preterm neonates. Independent quality assessment is important before introducing routine probiotic supplementation in this cohort. AIM: To assess product quality, and confirm that Bifidobacterium breve (B. breve) M-16V supplementation will increase fecal B. breve counts without adverse effects. METHODS AND PARTICIPANTS: Strain identity (16S rRNA gene sequencing), viability over 2 year shelf-life were confirmed, and microbial contamination of the product was ruled out. In a controlled trial preterm neonates (Gestation

+More

rrna gene sequencing viability identity fecal b breve counts contamination

Sanjay Patole,Anthony D Keil,Karen Simmer,Annie Chang,Elizabeth Nathan,Dorota Doherty,Meera Esvaran,Patricia Conway,.Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial.. 9 (3),.

Sanjay Patole,Anthony D Keil,Karen Simmer,Annie Chang,Elizabeth Nathan,Dorota Doherty,Meera Esvaran,Patricia Conway,"Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial." 9

Sanjay Patole,Anthony D Keil,Karen Simmer,Annie Chang,Elizabeth Nathan,Dorota Doherty,Meera Esvaran,Patricia Conway,"Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial."